Amgen 2002 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Page 12
innovation Medical breakthroughs occur at the intersection of
scientific discovery and market opportunity. Advanced biologics are
opening new avenues in the treatment of unmet medical needs. Amgen is
amassing the experience, resources, and talent needed to bridge those worlds
and create a new enterprise model for human therapeutic delivery.
research and
development
Discovery lies at the very core of Amgen’s identity. A pioneer in the biotechnology
revolution, the company for more than two decades has played a leadership role in the
translation of innovative science and technology into breakthrough human therapeutics.
Amgen research programs are grounded in the biological sciences, where advancing
technology and rapidly expanding knowledge allow the company to pursue the study of
disease and the development of potential new therapies at many levels. While Amgen
is best known for its expertise in protein therapeutics, the company also is developing
significant, complementary research capabilities in cell biology and synthetic chemistry,
with the ultimate goal of pursuing therapeutic possibilities wherever the scientific trail leads.
Such an aspiration must begin with a sound strategic approach. Amgen funds internal
discovery research programs organized around five therapeutic areas – hematology,
oncology, inflammation, neurology, and metabolic disorders. These programs are
enhanced and expanded through external research collaborations, acquisitions, and product
licensing opportunities.
Amgen’s genomics program uses the growing body of scientific knowledge about the
human genome to identify human proteins and growth factors implicated in disease